The following is a summary of “Off-label use of biologics in urticarial vasculitis: a European retrospective cohort study,” ...
The clinical efficacy of the biologic agents approved for the treatment of RA is also an important consideration when evaluating the cost of therapy, independent of dosing issues. [76] In a ...
"Starting in the 1980s and '90s, and then more recently, since the early 2000s, biologics have emerged, which are also used to treat rheumatoid arthritis." The first targeted biologic for RA ...
Biologics have been used to treat other inflammatory conditions, such as rheumatoid arthritis and psoriasis, for decades. Even so, they can still feel new to people with HS who are considering ...
Medication options are numerous for treating RA. They include over-the-counter (OTC) and prescription anti-inflammatory ...
In particular, agents that target tumour necrosis factor (TNF), a key inflammatory mediator in RA, are the leading biologic DMARDs (Fig. 1). Established therapies for RA have limitations related ...
The following is a summary of “Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease,” published in the January 2025 issue of ...
The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...
Switching among biologic therapies is common practice in patients with rheumatoid arthritis who have an inadequate response or intolerable adverse events. Evidence from observational studies and ...